"N Engl J Med"[journal] 检索结果

801. Insight into Corporate Governance - What Motivates Hospitals and Delivery Systems.

作者: Steven Lipstein.
来源: N Engl J Med. 2025年393卷13期1249-1251页

802. Goals for Opioid Use Disorder Medications - Protection, Remission, and Recovery.

作者: A Thomas McLellan.;Nora D Volkow.
来源: N Engl J Med. 2025年393卷13期1253-1255页

803. Hypertonic Saline or Carbocisteine in Bronchiectasis.

作者: Judy M Bradley.;Brenda O'Neill.;Daniel F McAuley.;James D Chalmers.;Anthony De Soyza.;Adam T Hill.;Mary Carroll.;Michael R Loebinger.;Jamie Duckers.;Mike Clarke.;Rebecca H McLeese.;Kathryn Ferguson.;Andrew Jackson.;Christina Campbell.;Clíona McDowell.;Ashley Agus.;John Norrie.;Fiona Copeland.;Damian G Downey.;Rory Convery.;Martin Kelly.;William Flight.;Nick P Talbot.;John R Hurst.;John Steer.;Muhammad Anwar.;Mitra Shahidi.;Timothy Gatheral.;Mohamed Etumi.;Anita L Sullivan.;Andreea Alina Ionescu.;Veeresh Patil.;Milan Bhattacharya.;Steven Caskey.;Denise Cosgrove.;Conor Hagan.;Amelia Shoemark.;Terence McManus.;Gareth Davies.;J Stuart Elborn.; .
来源: N Engl J Med. 2025年393卷16期1565-1577页

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness.

804. The Risks of Pharmaceutical Tariffs for Generic Drug Availability.

作者: Thomas J Hwang.;Quoc-Dien Trinh.;Kerstin N Vokinger.
来源: N Engl J Med. 2025年393卷13期1252-1253页

805. Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.

作者: Julian D Gillmore.;Ed Gane.;Jörg Täubel.;Björn Pilebro.;Andoni Echaniz-Laguna.;Justin Kao.;William Litchy.;Safi Shahda.;Alexandra Haagensen.;Liron Walsh.;Derek Smith.;Jessica Kachadourian.;Jonathan H Ward.;David Lebwohl.;Peijuan Zhu.;Yuanxin Xu.;Adia Leung.;Alison Sonderfan.;David E Gutstein.;Garen Manvelian.;David Adams.
来源: N Engl J Med. 2025年393卷14期1375-1386页

Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin (TTR) in peripheral nerves. Nexiguran ziclumeran (nex-z) is an investigational in vivo therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) that is designed to reduce serum TTR levels through selective inactivation of TTR in the liver.

806. Proliferation of Prior Authorization in Traditional Medicare - None the WISeR?

作者: Michael Liu.;Kushal T Kadakia.;Rishi K Wadhera.
来源: N Engl J Med. 2025年393卷15期1457-1459页

807. Risk and Benefit.

作者: Eric J Rubin.
来源: N Engl J Med. 2025年393卷15期1533-1534页

808. Permethrin-Treated Baby Wraps for the Prevention of Malaria.

作者: Ross M Boyce.;Bonnie E Shook-Sa.;Ronnie Ndizeye.;Emmanuel Baguma.;Dana Giandomenico.;Caitlin A Cassidy.;Solomon Eshun.;Mark J Siedner.;Sarah G Staedke.;Moses Ntaro.;Jonathan J Juliano.;Raquel Reyes.;Edgar M Mulogo.
来源: N Engl J Med. 2025年393卷14期1399-1408页

Malaria remains a major cause of childhood death in sub-Saharan Africa. We leveraged the traditional practice of mothers carrying children on their backs in cloth wraps to assess whether treating the wraps with an insect repellent might provide a layer of protection against malaria.

809. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. Reply.

作者: Christina Magnussen.;Thiess Lorenz.;Stefan Blankenberg.
来源: N Engl J Med. 2025年393卷12期1247-1248页

810. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.

作者: Lucia Cordero.;Daria Abasheva.;Alberto Ortiz.
来源: N Engl J Med. 2025年393卷12期1246-1247页

811. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.

作者: Samaneh Akbarpour.;Yosra Azizpour.;Bagher Larijani.
来源: N Engl J Med. 2025年393卷12期1246页

812. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.

作者: Xiaoni Zheng.;Jiameng Zhang.;Zhiyong Li.
来源: N Engl J Med. 2025年393卷12期1245-1246页

813. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.

作者: Kenneth H Cooper.
来源: N Engl J Med. 2025年393卷12期1245页

814. Cerebral Embolic Protection during TAVI. Reply.

作者: Rajesh K Kharbanda.;James Kennedy.;Matthew Dodd.
来源: N Engl J Med. 2025年393卷12期1244-1245页

815. Cerebral Embolic Protection during TAVI.

作者: Mengmeng Zhao.;Fan Ouyang.
来源: N Engl J Med. 2025年393卷12期1244页

816. Cerebral Embolic Protection during TAVI.

作者: Gaurav Sharma.
来源: N Engl J Med. 2025年393卷12期1243-1244页

817. Cerebral Embolic Protection during TAVI.

作者: Samir R Kapadia.
来源: N Engl J Med. 2025年393卷12期1243页

818. Nonoperative Management of Mismatch Repair-Deficient Tumors. Reply.

作者: Wassim Abida.;Luis A Diaz.;Andrea Cercek.
来源: N Engl J Med. 2025年393卷12期1242-1243页

819. Nonoperative Management of Mismatch Repair-Deficient Tumors.

作者: Christopher D Jakubowski.;Amit Verma.;Benjamin A Gartrell.
来源: N Engl J Med. 2025年393卷12期1241-1242页

820. CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis.

作者: Fabian Müller.;Raja Atreya.;Simon Völkl.;Michael Aigner.;Sascha Kretschmann.;Soraya Kharboutli.;Moritz Leppkes.;Selina Sitte.;Deike Strobel.;Arndt Hartmann.;Saurabh Mehandru.;Jean-Frederic Colombel.;Georg Schett.;Andreas Mackensen.;Markus F Neurath.
来源: N Engl J Med. 2025年393卷12期1239-1241页

结果排序

文献格式

出版时间

出版类型

出版语言